- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | CAMP4 Therapeutics: CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones | 100 | GlobeNewswire (Europe) | Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two... ► Artikel lesen | |
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.01. | Camp4 Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.11.24 | Camp4 Therapeutics GAAP EPS of -$24.19 | 1 | Seeking Alpha | ||
| 21.11.24 | CAMP4 Therapeutics: CAMP4 Reports Third Quarter 2024 Financial Results | 127 | GlobeNewswire (Europe) | - Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated... ► Artikel lesen | |
| 21.11.24 | Camp4 Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.11.24 | Camp4 Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | CAMP4 Analyst Highlights Rare Disease Platform Potential | 2 | Benzinga.com | ||
| 05.11.24 | Camp4 gains after earning bullish views on Street | 1 | Seeking Alpha | ||
| 05.11.24 | William Blair upbeat on CAMP4 shares with Outperform rating | 3 | Investing.com | ||
| 05.11.24 | Leerink sets stock target for CAMP4, cites broad UCD treatment potential | 2 | Investing.com | ||
| 05.11.24 | Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology | 1 | Investing.com | ||
| 05.11.24 | Piper Sandler optimistisch für CAMP4-Aktie, verweist auf Potenzial in bahnbrechender RNA-Technologie | 1 | Investing.com Deutsch | ||
| 05.11.24 | JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech | 4 | Investing.com | ||
| 16.10.24 | Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 15.10.24 | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.10.24 | CAMP4 stock edges up 2% following $75M IPO | 5 | Seeking Alpha | ||
| 11.10.24 | RNA biotech CAMP4 Therapeutics prices IPO below the range at $11; adds shares to keep deal size at $75 million | 2 | Renaissance Capital | ||
| 11.10.24 | CAMP4 Therapeutics prices $75MIPO at $11 per share | 1 | Seeking Alpha | ||
| 11.10.24 | CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh | 2 | Investing.com | ||
| 11.10.24 | Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4 | 1 | FierceBiotech |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| TEMPUS AI | 50,94 | 0,00 % | Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage von Nvidia an! | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 25,530 | -2,41 % | Edgewise Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| EVOTEC | 7,720 | -5,28 % | Evotec Aktie: Wechselwirkungen im internationalen Kontext | Die Evotec-Aktie verzeichnete am Handelstag einen bemerkenswerten Aufschwung und kletterte im XETRA-Handel um 5,3 Prozent auf 8,97 Euro. Das Handelsvolumen erreichte dabei 475.841 Aktien, wobei das... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 53,32 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,840 | 0,00 % | ADMA BIOLOGICS, INC. Q4 Earnings Summary | ||
| ARCELLX | 62,62 | 0,00 % | Arcellx GAAP EPS of -$2.00 misses by $0.40, revenue of $107.94M | ||
| AVIDITY BIOSCIENCES | 29,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights | Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational... ► Artikel lesen | |
| RADIOPHARM THERANOSTICS | 5,310 | 0,00 % | RADIOPHARM THERANOSTICS LIMITED: Half Year Report and Appendix 4D 31 December 2024 | ||
| PRAXIS PRECISION MEDICINES | 33,670 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update | BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| QIAGEN | 36,570 | -0,87 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (37,31 €) | Im Minus liegt zur Stunde die Aktie von Qiagen NV . Der jüngste Kurs betrug 37,31 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Verlust von 1,39 Prozent zu Buche. Die Aktie verbilligte... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 12,850 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting | ||
| DAY ONE BIOPHARMACEUTICALS | 8,245 | -9,10 % | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | ||
| TOURMALINE BIO | 12,330 | -5,59 % | Truist maintains $74 target on Tourmaline Bio stock, reiterates buy | ||
| STRUCTURE THERAPEUTICS | 22,360 | -5,53 % | Leerink cuts Structure Therapeutics target to $60, keeps outperform |
CAMP4 THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +17,85 % bei einem Aktienkurs von 4,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.
